Rick Polito

Rick Polito is a seasoned journalist covering the wellness industry.

🧪Questions consumers and clinicians ask TruthTide’s AI engine reveals interests and unknowns

Sep 10, 2026

•

4 min read

🧪Questions consumers and clinicians ask TruthTide’s AI engine reveals interests and unknowns

By Rick Polito, Peptides Business Wire editor

Rick Polito, +1

🧪Gyms provide a pathway to peptides, but can they do it legally?

Sep 3, 2026

•

4 min read

🧪Gyms provide a pathway to peptides, but can they do it legally?

By Rick Polito, Peptides Business Wire editor

Rick Polito, +1

Managing the practitioner-pharmacy relationship 🧪

Aug 27, 2026

•

5 min read

Managing the practitioner-pharmacy relationship 🧪

By Rick Polito, Peptides Business Wire editor

Rick Polito, +1

🧪Lilly lashes out at peptide sellers but will regulators act?

Aug 20, 2026

•

5 min read

🧪Lilly lashes out at peptide sellers but will regulators act?

By Rick Polito, Peptides Business Wire editor

Rick Polito, +1

Longevity makes peptide therapy a "relationship" 🧪

Aug 13, 2026

•

8 min read

Longevity makes peptide therapy a "relationship" 🧪

By Rick Polito, Peptides Business Wire editor

Rick Polito, +1

How peptides are reshaping sports medicine 🧪

Aug 6, 2026

•

11 min read

How peptides are reshaping sports medicine 🧪

By Rick Polito, Peptides Business Wire editor

Edward Mandel, +1

Is legal access to peptides inevitable? 🧪

Jul 29, 2026

•

11 min read

Is legal access to peptides inevitable? 🧪

By Rick Polito, Peptides Business Wire editor

Edward Mandel, +1

Jul 22, 2026

•

13 min read

Committee and Consequence 🧪

FDA’s Pharmacy Compounding Advisory Committee appears peptide-friendly but insiders predict no immediate greenlight. By Rick Polito, Peptides Business Wire editor

Rick Polito